These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16888216)

  • 21. NAP alpha-aminoisobutyric acid (IsoNAP).
    Gozes I; Schirer Y; Idan-Feldman A; David M; Furman-Assaf S
    J Mol Neurosci; 2014 Jan; 52(1):1-9. PubMed ID: 24458740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).
    Gozes I
    Curr Pharm Des; 2011; 17(31):3413-7. PubMed ID: 21902667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy.
    Ivashko-Pachima Y; Gozes I
    Prog Mol Biol Transl Sci; 2021; 177():65-90. PubMed ID: 33453943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein.
    Sari Y; Gozes I
    Brain Res Rev; 2006 Aug; 52(1):107-18. PubMed ID: 16488478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP.
    Gozes I
    Biol Chem; 2016 Mar; 397(3):177-84. PubMed ID: 25955282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.
    Ivashko-Pachima Y; Sayas CL; Malishkevich A; Gozes I
    Mol Psychiatry; 2017 Sep; 22(9):1335-1344. PubMed ID: 28115743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).
    Gozes I; Divinski I; Piltzer I
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S3. PubMed ID: 19091000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).
    Gozes I; Morimoto BH; Tiong J; Fox A; Sutherland K; Dangoor D; Holser-Cochav M; Vered K; Newton P; Aisen PS; Matsuoka Y; van Dyck CH; Thal L
    CNS Drug Rev; 2005; 11(4):353-68. PubMed ID: 16614735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity.
    Wilkemeyer MF; Chen SY; Menkari CE; Brenneman DE; Sulik KK; Charness ME
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8543-8. PubMed ID: 12808140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short neuroprotective peptides, ADNF9 and NAP, are structurally disordered and monomeric in PBS.
    Arakawa T; Niikura T; Arisaka F; Kita Y
    Int J Biol Macromol; 2009 Jul; 45(1):8-11. PubMed ID: 19447252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse.
    Sragovich S; Malishkevich A; Piontkewitz Y; Giladi E; Touloumi O; Lagoudaki R; Grigoriadis N; Gozes I
    Transl Psychiatry; 2019 Jan; 9(1):2. PubMed ID: 30664622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ameliorative effect of NAP on laser-induced retinal damage.
    Belokopytov M; Shulman S; Dubinsky G; Gozes I; Belkin M; Rosner M
    Acta Ophthalmol; 2011 Mar; 89(2):e126-31. PubMed ID: 21288307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methods of in vitro macrophage maturation confer variable inflammatory responses in association with altered expression of cell surface dectin-1.
    Gersuk GM; Razai LW; Marr KA
    J Immunol Methods; 2008 Jan; 329(1-2):157-66. PubMed ID: 17997408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein.
    Gozes I; Bassan M; Zamostiano R; Pinhasov A; Davidson A; Giladi E; Perl O; Glazner GW; Brenneman DE
    Ann N Y Acad Sci; 1999; 897():125-35. PubMed ID: 10676441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia.
    Dresner E; Agam G; Gozes I
    Eur Neuropsychopharmacol; 2011 May; 21(5):355-61. PubMed ID: 20598862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.
    Oz S; Ivashko-Pachima Y; Gozes I
    PLoS One; 2012; 7(12):e51458. PubMed ID: 23272107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.
    Shiryaev N; Jouroukhin Y; Giladi E; Polyzoidou E; Grigoriadis NC; Rosenmann H; Gozes I
    Neurobiol Dis; 2009 May; 34(2):381-8. PubMed ID: 19264130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis.
    Romano J; Beni-Adani L; Nissenbaum OL; Brenneman DE; Shohami E; Gozes I
    J Mol Neurosci; 2002; 18(1-2):37-45. PubMed ID: 11931348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus.
    Furman S; Hill JM; Vulih I; Zaltzman R; Hauser JM; Brenneman DE; Gozes I
    Neurosci Lett; 2005 Jan; 373(1):73-8. PubMed ID: 15555780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NAP mechanisms of neuroprotection.
    Gozes I; Steingart RA; Spier AD
    J Mol Neurosci; 2004; 24(1):67-72. PubMed ID: 15314252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.